- CA$81.92m
- CA$127.93m
- CA$57.56m
- 43
- 92
- 40
- 59
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1 | ||
| Price to Tang. Book | 1 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.23 | ||
| EV to EBITDA | 6.52 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.62% | ||
| Return on Equity | 12.14% | ||
| Operating Margin | 21.33% | ||
Financial Summary
| Year End 31st Aug | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 2.1 | 2.58 | 17.27 | 36 | 57.56 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Company’s brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.
Directors
- Zohar Krivorot PRE (42)
- Lennie Ryer CFO
- Besar Xhelili DRC (33)
- Thomas Faifull IND (70)
- Amy Satov IND
- Derek Stern IND (52)
- Last Annual
- August 31st, 2023
- Last Interim
- November 30th, 2023
- Incorporated
- October 19th, 2017
- Public Since
- January 14th, 2019
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 90,018,952
- Address
- Suite 2050 - 1055, West Georgia Street, VANCOUVER, V6E 3P3
- Web
- https://www.cannara.ca/en/
- Phone
- +1 5149139136
- Contact
- Nicholas Sosiak
- Auditors
- KPMG LLP
Upcoming Events for LOVE
Q3 2024 Cannara Biotech Inc Earnings Release
Similar to LOVE
ARCpoint
TSX Venture Exchange
Element Lifestyle Retirement
TSX Venture Exchange
Hempshire
TSX Venture Exchange
Jack Nathan Medical
TSX Venture Exchange
Leveljump Healthcare
TSX Venture Exchange
FAQ
What is the Cannara Biotech share price?
As of Today at 19:04 UTC, shares in Cannara Biotech are trading at CA$0.91. This share price information is delayed by 15 minutes.
How has the Cannara Biotech share price performed this year?
Shares in Cannara Biotech last closed at CA$0.91 and the price had moved by +7.06% over the past 365 days. In terms of relative price strength the Cannara Biotech share price has outperformed the Toronto Stock Exchange 300 Composite Index by +0.61% over the past year.
What are the analyst and broker recommendations for Cannara Biotech?
There is no consensus recommendation for this security.
What is the Cannara Biotech dividend yield?
Cannara Biotech does not currently pay a dividend.
Does Cannara Biotech pay a dividend?
Cannara Biotech does not currently pay a dividend.
When does Cannara Biotech next pay dividends?
Cannara Biotech does not currently pay a dividend.
How do I buy Cannara Biotech shares?
To buy shares in Cannara Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cannara Biotech?
As of the previous close price of CA$0.91, shares in Cannara Biotech had a market capitalisation of CA$81.92m.
Where are Cannara Biotech shares listed?
Here are the trading details for Cannara Biotech:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: LOVE
What kind of share is Cannara Biotech?
Based on an overall assessment of its quality, value and momentum Cannara Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cannara Biotech share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Cannara Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cannara Biotech. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -18.47%.
As of the last closing price of CA$0.91, shares in Cannara Biotech were trading -2.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cannara Biotech PE Ratio?
The Cannara Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cannara Biotech?
Cannara Biotech's management team is headed by:
- Zohar Krivorot - PRE
- Lennie Ryer - CFO
- Besar Xhelili - DRC
- Thomas Faifull - IND
- Amy Satov - IND
- Derek Stern - IND